Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
RNL Bio
Seoul, Seoul, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
RNL Bio completed Phase 2 trials of autologous stem cell therapies—Jointstem for osteoarthritis and Vascostem for Buerger's disease—in Korea; filed NDAs with KFDA and INDs with FDA; sought U.S. trials, but company faced severe financial and regulatory challenges and no product has reached market approval.
- Therapeutic areas
- NeurologyRheumatologyCardiovascularGastroenterology
- Modalities
- Cell therapyStem cell therapy
- Industry
- Biotech
02
Partnerships
BioLife Stem Cell Corp. (stem cell tech transfer)Human Biostar (direct-to-consumer stem cell banking)Johns Hopkins University School of Medicine (research MOU)
Beyond the preview
Go deeper on RNL Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNL Bio.